MaaT Pharma appointed new CSO
French MaaT Pharma has appointed Nathalie Corvaïa as Chief Scientific Officer and will strengthens its R&D Activities in Immuno-Oncology.
ADVERTISEMENT
About Maren Kühr
This author has not written his bio yet.
But we are proud to say that Maren Kühr contributed 192 entries already.
Entries by Maren Kühr
Health: still a defensive position in portfolios?
Healthcare has long been considered one of the most reliable defensive sectors – an effective portfolio buffer when equity markets turn volatile. That’s because hospitals, drug makers, medical device firms and other companies across the healthcare sector benefit from steady consumer demand – still true?
Biotechnology-driven carbon revolution
Fossil carbon is in nearly everything we use in our daily lives ranging from power and fuels to fibers, coatings, and materials used in our clothes, packaging, toys, and household goods. Virgin fossil carbon use in these products is not sustainable given the current understanding of the impact of extracted, emitted, and waste carbon on our environment, climate, and vulnerable populations.
Mimetas: New Chair of the Board
Leiden-based Mimetas, specialist in organ-on-chip-based disease models for drug discovery and development, has appointed Dhaval Patel (UCB, Belgium) as Chair of its Board of Directors.
Lytix Biopharma: CBO-Position new filled
Oslo-based Lytix Biopharma has a new Chief Business Officer. Stephen Worsley has started at the Norwegian immune-oncology company at the beginning of September.
New Head of Finance for Carbios
Finance Expert Pascal Bricout strengthens French Carbios as Chief of Strategy; Financial Officer and a member of the Executive Committee.
Ring exchange at Roche’s top executive level
Schwan follows Franz, Schinecker follows Schwan.
New president of Beckman Coulter Life Sciences
Beckman Coulter Life Sciences announces that Suzanne Foster has been appointed as president of the company. She succeeds Greg Milosevich, who has left the company.
Strengthening for Andera’s Life Sciences team
Jan Van den Bossche becomes the 20th partner of Andera Partners. He joined the Life Sciences team at the beginning of July to accelerate the deployment of its BioDiscovery 6 fund.
Charnwood Molecular with new CEO
Lee Patterson joins UK-based Charnwood Molecular as new CEO. After nearly 25 years at UK-based Charnwood Molecular, Prof. Steve Allin has stepping down as CEO. He will remain as an investor and Board advisor.